Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 44 of 49 for:    "Depressive Disorder" [DISEASE] AND Behavioral | ( Map: Belgium )

A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression. (RESTORE-LIFE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03320304
Recruitment Status : Recruiting
First Posted : October 25, 2017
Last Update Posted : July 11, 2019
Sponsor:
Information provided by (Responsible Party):
LivaNova

Brief Summary:
The primary objective of this study is to assess short, mid and long-term clinical outcomes in patients with difficult to treat depression (such as patients with treatment resistant depression) treated with Vagus Nerve Stimulation (VNS) Therapy as adjunctive therapy.

Condition or disease Intervention/treatment
Treatment Resistant Depression Device: Vagal Nerve Simulation (VNS) Therapy

Detailed Description:

The population under study comprises a real-world patient population with difficult to treat depression: patients diagnosed with unipolar or bipolar disorder with chronic or recurrent depression who fail to achieve an adequate response to standard psychiatric management.

The diagnosis of depression and comorbid disorders will be determined based on the Mini International Neuropsychiatric Interview (MINI).

A minimum of five hundred (500) patients will be implanted with a VNS Therapy System and up to eighty (80) sites may participate in this study.

Enrollment will take maximum 5 years, based on competitive enrollment. For each subject a baseline visit will occur between 1 and 6 weeks before implant.

Once implanted with the device, subjects will be followed-up for a minimum of 36 months and a maximum of 60 months.The study may stop when the last subject has reached the 36 months follow-up.


Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: A Global PRospective, Multi-cEnter, ObServational Post-markeT Study tO Assess shoRt, Mid and Long-term Effectiveness and Efficiency of VNS Therapy® as Adjunctive Therapy in reaL-world patIents With diFficult to Treat dEpression.
Actual Study Start Date : December 14, 2017
Estimated Primary Completion Date : December 1, 2023
Estimated Study Completion Date : December 1, 2025

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Vagal Nerve Simulation (VNS) Therapy
The aim of this study is to include patients with difficult to treat depression from a global "real world" (standard of care) population who are referred for treatment with VNS Therapy.
Device: Vagal Nerve Simulation (VNS) Therapy
A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.




Primary Outcome Measures :
  1. The primary endpoint of this study is response defined as reduction in Montgomery Åsberg Depression Rating Scale (MADRS) total score of at least 50% from baseline to 12 months post implant. [ Time Frame: 12 months ]

    MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Higher MADRS score indicates more severe depression.

    A 'Responder' is a subject that achieved ≥ 50% reduction from baseline in MADRS total score at the M12 assessment. A 'Non-Responder' is any patient who did not achieve ≥ 50% reduction from baseline in MADRS score at the M12 assessment.

    No formal hypothesis testing is presented; all the proposed statistical tests are descriptive in nature.

    The Primary endpoint analysis as defined above will be done only on patients that are enrolled while in a major depressive episode (MDE); the cut off point for current MDE at time of implant will be a MADRS score of 20.

    For the patients with a MADRS score below 20 at time of enrollment, only the continuous change in MADRS can be described (as the MADRS can only worsen or stay the same).



Secondary Outcome Measures :
  1. Duration of response [ Time Frame: through study completion, an average of 4 years ]
    computed as the difference between the first recorded date post baseline that response is achieved (MADRS reduction from baseline ≥ 50%) and the first date at which MADRS again increased to a level of <40% from baseline.

  2. Change in MADRS [ Time Frame: through study completion, an average of 4 years ]
    Change in MADRS over time

  3. Cumulative response [ Time Frame: through study completion, an average of 4 years ]
    Cumulative percentage of first-time MADRS responders (MADRS reduction from baseline ≥ 50%) at any post-baseline visit.

  4. Cumulative remission [ Time Frame: through study completion, an average of 4 years ]
    Cumulative percentage of subjects in remission (MADRS ≤9) at any post-baseline visit.

  5. Changes in depression score As measured by the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR). [ Time Frame: through study completion, an average of 4 years ]
    The Quick Inventory of Depressive Symptomatology (QIDS-SR) is a 16-item, subject-completed questionnaire of the symptoms of mood and depression. The total score ranges from 0 to 27. A higher QIDS-SR score indicates a more severe depression.

  6. Changes in mania score as measured by the Altman Self-Rating Mania Scale (ASRM)*. [ Time Frame: through study completion, an average of 4 years ]

    *Optional assessments: to be done at selected sites only and based on investigator's clinical judgment to decide which subjects complete them.

    The Altman Self-rating Mania Scale (ASRM) is a 5-item self-reported diagnostic scale which can be used to assess the presence and severity manic and hypomanic symptoms, most commonly in patients diagnosed with bipolar disorder. The total score ranges from 0 to 20. A score of 6 or higher indicates a high probability of a manic or hypomanic condition.


  7. Changes in Quality of Life as measured by the EuroQol five dimensions questionnaire (EQ-5D-5L) [ Time Frame: through study completion, an average of 4 years ]
    The EuroQol five dimensions questionnaire (EQ-5D-5L) is a standardized 5-item subject completed questionnaire measuring generic health status and quality of life.

  8. Changes in patient function as measured by the Work Productivity and Activity Impairment Scale (WPAI) [ Time Frame: through study completion, an average of 4 years ]
    The Work Productivity and Activity Impairment Questionnaire (WPAI) is a subject self-reported 6-item questionnaire that measures impairments in work and activities. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

  9. Changes in Quality of Life and patient function as measured by the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) [ Time Frame: through study completion, an average of 4 years ]
    The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) is a standardized 16-item, self-report scale to assess the degree of enjoyment and satisfaction experienced by the subject during the past week.

  10. Changes in suicidality as measured by item #10 of MADRS. [ Time Frame: through study completion, an average of 4 years ]
    Item 10 on the Montgomery-Åsberg Depression Rating Scale (MADRS) scale assesses suicidal thoughts as representing the feeling that life is not worth living, that a natural death would be welcome, suicidal thoughts and preparations for suicide and is rated from 0 to 6. A score of ≥ 4 ('probably better off dead') is of particular interest.

  11. Changes in suicidality as measured by item #12 of QIDS-SR. [ Time Frame: through study completion, an average of 4 years ]
    For Item 12 of the Quick Inventory of Depressive Symptomatology (QIDS-SR), the subject assesses any thoughts of death or suicide over the previous 7 days on a 4- point scale; a score of ≥ 2 ('I think of suicide or death several times a week for several minutes') being of interest.

  12. Changes in adjunctive antidepressant pharmacological treatment [ Time Frame: through study completion, an average of 4 years ]
    All adjunctive concomitant antidepressant and psychotropic medications will be collected

  13. Changes in adjunctive antidepressant non-pharmacological treatment [ Time Frame: through study completion, an average of 4 years ]
    The following adjunctive non-pharmacological treatments will be collected: maintenance electroconvulsive therapy (ECT), Transcranial Magnetic Stimulation (TMS) and psychotherapy

  14. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: through study completion, an average of 4 years ]
    The following adverse events will be collected: serious adverse events, deaths, VNS Therapy related adverse events and device deficiencies.

  15. Changes in cognition [ Time Frame: through study completion, an average of 4 years ]

    As measured by THINC-it® Tool*.

    *Optional assessments: to be done at selected sites only and based on investigator's clinical judgment to decide which subjects complete them.


  16. Changes in anxiety as measured by the Generalized Anxiety Disorder Assessment (GAD 7)*. [ Time Frame: through study completion, an average of 4 years ]

    *Optional assessments: to be done at selected sites only and based on investigator's clinical judgment to decide which subjects complete them.

    The Generalized Anxiety Disorder 7 (GAD-7) is a 7-item self-reported questionnaire for screening and severity measuring of generalized anxiety disorder (GAD). GAD-7 has seven items and uses a normative system of scoring. Assessment is indicated by the total score, which made up by adding together the scores for the scale all seven items.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The population under study comprises a real-world patient population with difficult to treat depression: patients diagnosed with unipolar or bipolar disorder with chronic or recurrent depression who fail to achieve an adequate response to standard psychiatric management.

The diagnosis of depression and comorbid disorders will be determined based on the Mini International Neuropsychiatric Interview (MINI).

Criteria

Inclusion Criteria:

  • Be at least 18 years of age.
  • Have a documented primary diagnosis of chronic (>2 years) or recurrent (2 or more prior episodes) major depressive episode that has not adequately responded to an adequate number of antidepressant treatments, as per local medical standards. This diagnosis must be confirmed using the MINI.
  • Provide written Ethics Committee (EC) or Institutional Review Board (IRB) approved informed consent and Health Insurance Portability and Accountability Act (HIPAA, US only) authorization (as applicable according to local requirements).
  • Currently is receiving at least one antidepressant treatment (i.e., antidepressant drug, maintenance electroconvulsive therapy, or formal psychotherapy including supportive psychotherapy) or mood stabilizing treatment for bipolar patients (such as lithium, anticonvulsants, or atypical antipsychotics).
  • Able and willing to comply with the frequency of (outpatient) clinic visits and to reliably complete all the evaluations as specified in the study protocol.Hence based on the nature of their disease, the following patients should not be included: patients with mental retardation, current severe or significant substance/alcohol abuse, diagnosis of one or more schizophrenia-spectrum or other psychotic disorders, diagnosis of borderline or severe personality disorder as determined by clinical judgment which, in the investigator's opinion, would significantly interfere with subject's participation in the study)

Exclusion Criteria:

There are no exclusion criteria; the investigator should refer to the (local applicable) VNS Therapy Physician's Manual.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03320304


Contacts
Layout table for location contacts
Contact: An Scheltens 0032479458379 an.scheltens@livanova.com
Contact: Renske De Zwaef 0032498644704 renske.dezwaef@livanova.com

Locations
Layout table for location information
Belgium
KU Leuven Recruiting
Leuven, Belgium
Contact: Koen Demyttenaere         
Germany
Universitätsklinikum Bonn Recruiting
Bonn, Germany
Contact: Helge Müller         
Universitätsklinikum Frankfurt Recruiting
Frankfurt, Germany
Contact: Christine Reif-Leonhard         
Universitätsklinikum Freiburg Recruiting
Freiburg, Germany
Contact: Thomas Schläpfer         
Universitätsmedizin Göttingen Not yet recruiting
Göttingen, Germany
Contact: Claus Wolff-Menzler         
Medizinische Hochschule Hannover Not yet recruiting
Hannover, Germany
Contact: Helge Frieling         
Contact: Kai Kahl         
Universitätsklinikum Jena Recruiting
Jena, Germany
Contact: Karl-Jürgen Bär         
Universitätsklinikum Köln Recruiting
Köln, Germany
Contact: Fritz-Georg Lehnhardt         
Klinikum Wilhelmshaven Recruiting
Wilhelmshaven, Germany
Contact: Here Folkerts         
United Kingdom
Glenfield hospital Recruiting
Leicester, United Kingdom, LE3 9EJ
Contact: Girish Kunigiri         
King's College London Recruiting
London, United Kingdom
Contact: Allan Young         
Academic Psychiatry Wolfson Research Centre Recruiting
Newcastle Upon Tyne, United Kingdom
Contact: Hamish McAllister-Williams         
Mendip HTT / St Andrew's Ward Not yet recruiting
Wells, United Kingdom, BA5 1TH
Contact: Andreas Papadopoulos         
Sponsors and Collaborators
LivaNova
Investigators
Layout table for investigator information
Principal Investigator: Koen Demyttenaere, Prof. KU Leuven
Principal Investigator: Allan Young, Prof. King's College

Additional Information:

Layout table for additonal information
Responsible Party: LivaNova
ClinicalTrials.gov Identifier: NCT03320304     History of Changes
Other Study ID Numbers: LNN800
First Posted: October 25, 2017    Key Record Dates
Last Update Posted: July 11, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Keywords provided by LivaNova:
Difficult to Treat Depression
TRD
VNS Therapy
Vagus Nerve Stimulation
VNS
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Behavioral Symptoms
Mood Disorders
Mental Disorders